Mark Murray compensation by year
Arbutus Biopharma Summary Compensation Table · all 3 fiscal years held| Component | FY2017 | FY2018 | FY2019 |
|---|---|---|---|
| Salary | $540,000 | $556,000 | $273,491 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 |
| Option awards | $1,003,500 | $1,610,020 | $1,193,684 |
| Non-equity incentive | $324,000 | $306,000 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $47,794 | $55,865 | $2,313,255 |
| Total | $1,915,294 | $2,527,885 | $3,780,430 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arbutus Biopharma Corp DEF 14A filed April 24, 2020, accession 0001047469-20-002560, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Arbutus Biopharma Corp filed document, accession 0001047469-20-002560. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2020.
Equity holdings
unvested awards at FY2019 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 150,000 | — | $3.15 |
| Option | 357,500 | — | $4.57 |
| Option | 418,187 | — | $5.20 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Arbutus Biopharma Corp's FY2019 proxy; value at the fiscal year-end close, as the company printed it.
Arbutus Biopharma’s named executive officers, FY2019
as the company reported each| Named executive officer | Role | FY2019 total |
|---|---|---|
| Mark Murray · this page | Former President and Chief Executive Officer | $3,780,430 |
| William Collier | President and Chief Executive Officer | $2,334,185 |
| Michael Sofia | Chief Scientific Officer | $1,051,388 |
| David Hastings | Chief Financial Officer | $1,010,250 |
The full Arbutus Biopharma compensation record
free company briefThis page is one person within Arbutus Biopharma's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arbutus Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.